Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solifenacin versus tolterodine for primary nocturnal enuresis in children
IRCT20220520054929N1Phase 3Completed
- Sponsor
- Zahedan University of Medical Sciences
- Start
- Sep 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of solifenacin and tolterodine in nocturnal enuresis (NE) (2 arms), sponsored by Zahedan University of Medical Sciences. Primary endpoints: Number of enuresis episodes, Treatment satisfaction and 2 more. Started Sep 2022; status: completed.
02
Drugs
solifenacintolterodine
03
Conditions
nocturnal enuresis (NE)
Beyond the preview
Go deeper on IRCT20220520054929N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220520054929N1.